AxoGen, Inc. (AXGN) Director Jamie Mark Grooms Sells 21,290 Shares of Stock
AxoGen, Inc. (NASDAQ:AXGN) Director Jamie Mark Grooms sold 21,290 shares of AxoGen stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $26.22, for a total transaction of $558,223.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jamie Mark Grooms also recently made the following trade(s):
- On Friday, December 8th, Jamie Mark Grooms sold 84,295 shares of AxoGen stock. The shares were sold at an average price of $26.38, for a total transaction of $2,223,702.10.
Shares of AxoGen, Inc. (NASDAQ:AXGN) traded down $0.25 during mid-day trading on Friday, hitting $26.20. 362,806 shares of the stock were exchanged, compared to its average volume of 374,501. AxoGen, Inc. has a 12-month low of $8.15 and a 12-month high of $27.60. The company has a quick ratio of 2.95, a current ratio of 3.55 and a debt-to-equity ratio of 1.93.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC lifted its stake in shares of AxoGen by 27.8% during the 3rd quarter. Pura Vida Investments LLC now owns 229,278 shares of the medical equipment provider’s stock valued at $4,437,000 after buying an additional 49,909 shares in the last quarter. Neuberger Berman Group LLC lifted its stake in shares of AxoGen by 133.3% during the 3rd quarter. Neuberger Berman Group LLC now owns 28,000 shares of the medical equipment provider’s stock valued at $542,000 after buying an additional 16,000 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of AxoGen by 4.9% during the 3rd quarter. California Public Employees Retirement System now owns 137,536 shares of the medical equipment provider’s stock valued at $2,661,000 after buying an additional 6,436 shares in the last quarter. Bamco Inc. NY purchased a new position in shares of AxoGen during the 3rd quarter valued at $3,443,000. Finally, Valeo Financial Advisors LLC purchased a new position in shares of AxoGen during the 3rd quarter valued at $244,000. Institutional investors own 66.00% of the company’s stock.
A number of equities research analysts have recently issued reports on the stock. Leerink Swann reissued an “outperform” rating and set a $23.00 price objective (up previously from $22.00) on shares of AxoGen in a research report on Saturday, September 30th. Cantor Fitzgerald reissued a “buy” rating and set a $18.00 price objective on shares of AxoGen in a research report on Monday, August 21st. Jefferies Group assumed coverage on shares of AxoGen in a research report on Thursday, November 30th. They set a “buy” rating and a $35.00 price objective for the company. Wedbush reissued a “buy” rating and set a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research report on Tuesday, November 21st. Finally, Lake Street Capital boosted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 21st. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $26.17.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/09/axogen-inc-axgn-director-jamie-mark-grooms-sells-21290-shares-of-stock.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Stock Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related stocks with our FREE daily email newsletter.